EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world safety profile of roflumilast: a pharmacovigilance analysis using FDA adverse event reporting system and Canada vigilance database

Rui Xu, Hui Peng, Chang Shu, Maochang Liu, Ping Gao

Journal of Pharmacy & Pharmaceutical Sciences · 2026

DOI: 10.3389/jpps.2025.15678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2026. Verfasst von Rui Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Scie…. Hauptthemen laut MEDLINE: Benzamides, Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Aminopyridines. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Roflumilast, a highly selective phosphodiesterase 4 inhibitor, is used to treat with chronic obstructive pulmonary disease and psoriasis. We aim to determine potential roflumilast-associated adverse events (AEs) and the differences in AE signals among diverse populations.

Methods

Roflumilast’s AE reports between the first quarter of 2011 and the fourth quarter of 2024 were obtained from the FDA Adverse Event Reporting System (FAERS) and Canada Vigilance Adverse Reaction Database (CVARD). The signal strength was measured by four disproportionality analysis methods, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).

Results

In FAERS, population aged ≥65 years and oral medication users accounted for a predominant proportion in the reported cases. FDA-unlabeled respiratory, thoracic and mediastinal disorders was the only one signal categorized by system organ class met all four algorithms. Newly identified AEs such as dyspnea, condition aggravated, cough, and tachycardia could contribute valuable safety considerations for clinical practice. The analysis of the available time-to-onset data suggested that cases often occurred within the first 30 days post-treatment. These results were externally validated in CVARD, suggesting consistent findings. Notably, headache was more frequently reported among users of topical formulations and female patients, while suicidal ideation and weight loss were more commonly reported in male patients and oral medications, respectively.

Conclusion

This study confirmed established adverse reactions and identified novel AEs in real-world clinical practice by dual-database pharmacovigilance analysis. Clinicians should remain vigilant for AEs that differ by gender and route to enable early intervention and improve prognosis. The findings highlight personalized safety management, while underscoring the necessity of prospective studies to validate results and further characterize roflumilast’s safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesPharmacovigilanceAdverse Drug Reaction Reporting SystemsAminopyridinesPhosphodiesterase 4 InhibitorsCyclopropanesHumansFemaleMaleUnited StatesCanadaUnited States Food and Drug AdministrationDatabases, FactualAgedMiddle AgedAdultYoung AdultAged, 80 and overAdolescent

Stichwörter der Autor:innen

CVARDFAERSadverse eventsdisproportionality analysisroflumilast

Substanzen

RoflumilastCyclopropanesBenzamidesAminopyridinesPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Zitieren

APA

Xu, R., Peng, H., Shu, C., Liu, M., & Gao, P. (2026). Real-world safety profile of roflumilast: a pharmacovigilance analysis using FDA adverse event reporting system and Canada vigilance database. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2025.15678

Vancouver

Xu R, Peng H, Shu C, Liu M, Gao P. Real-world safety profile of roflumilast: a pharmacovigilance analysis using FDA adverse event reporting system and Canada vigilance database. Journal of Pharmacy & Pharmaceutical Sciences. 2026. doi:10.3389/jpps.2025.15678

BibTeX
@article{Xu2026,
  author = {Xu, Rui and Peng, Hui and Shu, Chang and Liu, Maochang and Gao, Ping},
  title = {Real-world safety profile of roflumilast: a pharmacovigilance analysis using FDA adverse event reporting system and Canada vigilance database},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2026},
  doi = {10.3389/jpps.2025.15678}
}
Kostenlos starten →